Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease"
- PMID: 34774637
- DOI: 10.1016/j.jhep.2021.11.003
Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease"
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.J Hepatol. 2021 Aug;75(2):454-461. doi: 10.1016/j.jhep.2021.05.003. Epub 2021 May 19. J Hepatol. 2021. PMID: 34019941
-
MAFLD supported by 95.45% participants of CSH is NOT representative.J Hepatol. 2022 Feb;76(2):481-482. doi: 10.1016/j.jhep.2021.06.012. Epub 2021 Jun 19. J Hepatol. 2022. PMID: 34153397 No abstract available.
-
One not like the other: The weakness of the blood sugar-MAFLD analogy.J Hepatol. 2022 Feb;76(2):482-484. doi: 10.1016/j.jhep.2021.10.010. Epub 2021 Oct 20. J Hepatol. 2022. PMID: 34678406 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
